Why European Logistics Must Route Smarter, Not Harder Amid Driver Shortage

Pharma cold chain last mile Europe operations are under pressure from two directions at once: tighter expectations for product integrity and a shrinking pool of transport capacity.

For temperature-controlled medicines, the last mile is no longer a simple delivery leg from depot to door. It is the point where validated packaging, driver behaviour, traffic, time windows, hospital receiving processes, pharmacy opening hours, temperature monitoring, and proof of delivery all converge. One missed delivery, excessive dwell time, poor route sequencing, or late exception response can turn a compliant shipment into a temperature excursion.

Industry commentary often frames pharma cold chain failure as a $35B problem. The number matters, but the operational lesson matters more: a large share of preventable risk sits in execution, not just packaging or storage. In Europe, that execution layer is especially complex. Dense city centres, fragmented pharmacy and hospital networks, cross-border movements, driver shortages, and GDP requirements make static routing increasingly inadequate.

Pharma manufacturers, wholesalers, healthcare distributors, and 3PLs cannot solve this by adding more vehicles, more manual dispatchers, or more buffer packaging alone. They need last-mile orchestration that can plan around cold chain constraints, adapt routes in real time, protect SLA adherence, reduce cost-to-serve, and create auditable records for quality teams.

That is where Locus fits: not as a packaging or sensor provider, but as the AI-powered dispatch and route optimisation layer that connects orders, vehicles, drivers, time windows, temperature-sensitive priorities, and execution data into one operating model.

For 2026 planning, the operating context has become sharper. The Europe pharmaceutical cold chain logistics market is projected by Mordor Intelligence to reach USD 22.58 billion in 2026, with transportation services accounting for 61.76% of market share in the reported 2025 base year. In other words: the transport layer is not a supporting function. It is where market growth, compliance risk, patient service, and cost control increasingly converge.

Key Takeaways

• Pharma cold chain last-mile delivery in Europe refers to the temperature-controlled movement of medicines, vaccines, biologics, clinical trial products, and specialty therapies from depots or wholesalers to hospitals, pharmacies, clinics, homes, or patients while maintaining validated conditions and GDP-compliant documentation.
• The last mile is a high-risk point because multi-stop routes, door-open events, traffic delays, failed deliveries, and long dwell times erode temperature hold time and increase the probability of excursions.
• Common pharma temperature requirements include controlled ambient, refrigerated 2–8°C, frozen, and ultra-low or cryogenic ranges such as around -80°C, depending on the product and protocol.
• EU Good Distribution Practice, EMA expectations, and national regulators require transport conditions, monitoring, documentation, training, and quality controls that extend into last-mile execution.
• Europe’s wider driver shortage compounds cold chain risk: Europe recorded 426,000 unfilled truck driver positions in 2024, and the deficit is projected to reach 745,000 by 2028.
• AI-powered route optimisation helps pharma and healthcare logistics networks prioritise temperature-sensitive stops, reduce avoidable miles and dwell time, improve on-time delivery, and provide route-level audit trails.
• Locus helps enterprise operators orchestrate cold chain last mile by combining route planning, dispatch automation, real-time resequencing, SLA monitoring, driver guidance, and execution analytics.

Optimise Pharma Cold Chain Routes with Locus

See how Locus helps healthcare logistics teams improve on-time delivery, dispatch control, route productivity, and SLA adherence across temperature-sensitive last-mile networks.

Schedule A Demo

What Is Pharma Cold Chain Last-Mile Delivery in Europe?

Pharma cold chain last-mile delivery in Europe is the temperature-controlled movement of medicinal products from a distribution centre, wholesaler, depot, pharmacy distribution centre, or specialist logistics hub to the final point of care or dispensing. That final point may be a hospital ward, community pharmacy, clinic, laboratory, clinical trial site, home healthcare address, or patient.

The goal is not simply to arrive. The goal is to arrive on time, within validated temperature conditions, with a complete audit trail.

In practical terms, last-mile pharmaceutical cold chain logistics in Europe must coordinate three layers at once:

1. Product integrity: maintaining the required temperature band and validated handling conditions.
2. Service reliability: meeting appointment windows, clinical schedules, pharmacy opening hours, and patient availability.
3. Compliance evidence: capturing proof of delivery, handoff records, exception data, and chain-of-custody information suitable for GDP and quality review.

This is why last-mile pharma cold chain is not the same problem as standard parcel delivery. Delivery density matters, but it cannot override product sensitivity, route duration, packaging hold time, driver training, receiving-site constraints, or deviation management.

Last-Mile Pharma Cold Chain Checklist for Europe

A GDP-aligned last-mile network should include:

• Validated packaging or qualified temperature-controlled vehicles for the required temperature range
• Route risk assessment by product type, delivery geography, and receiving-site complexity
• Shipment priority rules for urgent, patient-specific, or short-hold-time products
• Real-time visibility into route progress, ETA risk, failed deliveries, and exceptions
• Temperature monitoring and data logging where required by product, lane, and quality SOP
• Driver training for GDP handling, handoff, returns, documentation, and exception escalation
• Appointment-aware routing for hospitals, pharmacies, clinics, laboratories, and home deliveries
• Documented proof of delivery and chain-of-custody capture
• SOPs for temperature excursions, failed deliveries, returns, and corrective action
• Audit-ready route, delivery, and exception records that quality teams can investigate

The Cold Chain Time Bomb: Regulation, Capacity, and Last-Mile Complexity

For pharma logistics leaders, the last mile has become the most operationally volatile part of the cold chain. Warehouses can be qualified. Packaging can be validated. Vehicles can be temperature-controlled. But once a driver leaves the depot with a mixed sequence of hospital, pharmacy, clinic, and patient deliveries, the operating environment becomes dynamic.

A compliant cold chain route must account for:

• Product temperature range and validated hold time
• Vehicle type and compartment capability
• Passive packaging duration
• Stop priority and clinical urgency
• Delivery appointment windows
• Driver skills and GDP training requirements
• Receiving-site access constraints
• Door-open events and dwell time
• Failed delivery and return workflows
• Proof of delivery and chain-of-custody capture
• Temperature alerts and exception escalation

In Europe, these constraints sit on top of dense urban networks, cross-border requirements, fragmented healthcare delivery models, and ongoing driver capacity pressure.

The rise of temperature-sensitive medicines

Pharma portfolios increasingly include high-value biologics, vaccines, specialty medicines, cell and gene therapies, and advanced therapy medicinal products. These products often require stricter handling than traditional ambient medicines.

The growth is visible in the market data. Mordor Intelligence reports that chilled products shipped at 2–8°C represent 40.88% of the Europe pharmaceutical cold chain logistics market by temperature type in the 2025 base year, reflecting the dominance of vaccines and monoclonal antibodies in this range. The same source reports that deep-frozen and ultra-low-temperature services are projected to grow at a 5.61% CAGR between 2026 and 2031, driven by scaling cell and gene therapies.

Typical temperature profiles include:

Product / shipment type	Typical temperature requirement	Last-mile sensitivity
Many vaccines and biologics	2–8°C	High risk from route delay, door-open events, and failed first delivery
Some specialty medicines	Controlled ambient or refrigerated	Requires time-window discipline and documented custody
Frozen therapies and materials	-20°C or lower	Requires strict packaging and route duration control
Ultra-low / cryogenic therapies	Around -80°C or cryogenic, depending on protocol	Often time-critical and patient- or procedure-specific
Clinical trial products	Protocol-specific	Requires chain-of-custody, documented handoff, and exception traceability

The more valuable and time-sensitive the product, the less tolerance there is for routing imprecision. For a deeper look at the product and network pressures behind this shift, see Locus’s perspective on biopharmaceutical cold chain logistics challenges.

Europe pharmaceutical cold chain market signals that matter for last mile

Market signal	What the data shows	Why it matters for last-mile execution
Europe pharma cold chain logistics market	Projected by Mordor Intelligence to reach USD 22.58 billion in 2026	More volume and value are moving through temperature-controlled transport networks
Transportation share	Transportation services accounted for 61.76% of market share in the 2025 base year, per Mordor Intelligence	The delivery execution layer carries a disproportionate share of cold chain cost and risk
Chilled 2–8°C products	Chilled products represented 40.88% of the market by temperature type in the 2025 base year, per Mordor Intelligence	Refrigerated last-mile routing must handle high-volume vaccines, biologics, and monoclonal antibodies reliably
Branded drugs	Branded drugs accounted for 56.34% of the market by product type in the 2025 base year, per Mordor Intelligence	High-value products increase the financial impact of failed deliveries, excursions, and write-offs
Specialty and orphan drugs	Forecast by Mordor Intelligence to grow at a 5.91% CAGR through 2031	More patient-specific, time-sensitive deliveries increase the need for precise orchestration
Biotech and biosimilar manufacturers	Expected by Mordor Intelligence to grow at a 6.27% CAGR from 2026 to 2031	Emerging therapy portfolios demand stronger route planning, visibility, and exception control
Passive packaging	Estimated by Future Market Insights to account for 72.5% of pharmaceutical cold chain packaging consumption in 2026	Passive shippers make route duration, stop sequence, and dwell time especially important
Monitoring compliance	Technavio reports that European cold chain firms implementing advanced monitoring systems report over 99.8% compliance with temperature requirements during transit for pharmaceutical shipments	Monitoring improves visibility, but route orchestration is needed to act before alerts become deviations

Europe’s driver shortage makes cold chain harder to execute

Cold chain performance also depends on people. Drivers must follow SOPs, protect shipments during handoff, avoid unnecessary door openings, manage returns properly, and execute proof-of-delivery processes. When driver capacity is constrained, routes become longer, training gaps widen, and dispatch teams have less flexibility to recover from disruption.

Europe’s wider road transport capacity problem is material. According to ResearchAndMarkets.com, Europe recorded 426,000 unfilled truck driver positions in 2024. The International Road Transport Union projects that deficit could reach 745,000 by 2028, and the IRU has warned that Europe could lack over two million transport drivers by 2026 across all road sectors.

For pharma cold chain operations, this means fewer spare drivers, less contingency capacity, and higher risk when static plans fail.

The regulatory squeeze

EU Good Distribution Practice places clear expectations on medicinal product distribution, including appropriate storage and transport conditions, prevention of contamination, trained personnel, documentation, and quality systems. The European Commission GDP guidelines and European Medicines Agency GDP information make one point operationally unavoidable: transport is part of the quality system.

That has direct implications for last mile:

• Routes must be designed with risk in mind, not only distance.
• Temperature-sensitive shipments need appropriate monitoring and documentation.
• Deviations require timely escalation and corrective action.
• Transport partners must be qualified and trained.
• Records must be complete enough to support audits and investigations.

A route that is cheap but repeatedly creates late arrivals, missed time windows, excessive dwell time, or undocumented exceptions is not a compliant operating model.

---

Which European Last-Mile Networks Face the Highest Cold Chain Risk?

Cold chain risk is not evenly distributed across Europe. It varies by network density, healthcare model, urban access, country-specific regulations, cross-border complexity, and product mix.

Country / Region	Common last-mile complexity	Cold chain operating risk
Germany	Large pharmacy and hospital network; strict delivery windows; urban and regional mix	Sequencing, receiving-site dwell time, route duration control
France	Dense urban centres; hospital access constraints; regional distribution complexity	Parking restrictions, failed delivery recovery, SLA adherence
United Kingdom	Post-Brexit cross-border complexity; MHRA oversight; fragmented capacity in some lanes	Customs-adjacent delays, driver availability, documentation discipline
Benelux	High cross-border movement; dense delivery geography	Multi-country routing, handoff consistency, traffic volatility
Spain	Long regional distances combined with major urban delivery zones	Route duration, heat exposure risk, depot-to-city timing
Italy	Older city layouts and restricted access zones	Vehicle access, parking dwell time, appointment reliability
Nordics	Longer distances and weather variability	Route resilience, contingency planning, delivery predictability

This is why generic route planning is insufficient. A route that works for ambient retail delivery may fail in pharma because it ignores validated hold time, stop priority, route qualification, receiving constraints, and GDP documentation.

The Brexit compounding effect

The UK’s departure from the EU added operational complexity for logistics networks moving between the UK and continental Europe. The UK also experienced acute driver disruption after Brexit. Approximately 15,000 Eastern European drivers left the UK, contributing to wider capacity pressure.

For healthcare 3PLs operating across France, Germany, Benelux, and the UK, these regional pressures make intelligent route optimisation software a control mechanism, not a back-office convenience.

How Europe’s pharma cold chain last mile differs from the US and Asia

Europe’s last-mile cold chain problem has its own operating profile:

• Compared with the US: Europe has shorter average distances in many urban and regional lanes, but more cross-border variation, language complexity, local access rules, and national regulatory overlays. US networks often have more centralised national scale; European networks often require more country-level configuration.
• Compared with Asia: Europe generally has mature GDP frameworks and strong healthcare infrastructure, but older city layouts, low-emission zones, restricted access areas, and fragmented pharmacy models create intense last-mile constraints. In parts of Asia, infrastructure variability and long-distance temperature exposure may dominate the risk profile.
• For home healthcare: Europe’s ageing population and specialty therapy growth are increasing patient-centric delivery requirements. Home delivery of biologics and specialty medicines demands precise time windows, recipient validation, and reliable exception management. See Locus’s view on pharmacy home delivery efficiency for more on this shift.

---

The Silent Cold Chain Productivity Killers

If the product is temperature-sensitive and the driver’s available hours are constrained, every avoidable delay matters. In pharma last mile, productivity leakage is not only a cost issue. It can become a quality risk.

Door-open events and dwell time

Every stop creates thermal risk. The driver parks, opens doors or compartments, locates the package, completes handoff, captures proof of delivery, and moves to the next stop. Poor sequencing increases the number and duration of exposure events.

In a multi-stop pharmacy or hospital route, small delays compound quickly:

• A loading delay at the depot shortens available packaging hold time.
• A difficult first delivery pushes the whole sequence late.
• An urgent hospital stop may be reached after lower-priority deliveries if the route is not constraint-aware.
• Failed delivery creates a return movement that was not planned into the cold chain risk model.

Route optimisation must therefore account for more than kilometres. It must model time, service duration, priority, product sensitivity, and delivery feasibility.

Traffic, failed deliveries, and unplanned detours

Urban Europe is unforgiving. Paris, London, Milan, Amsterdam, Berlin, Madrid, and other major cities bring access restrictions, congestion, kerbside limitations, and delivery time-window constraints.

For ambient parcels, a delay may create customer dissatisfaction. For pharma, it may also threaten:

• Packaging hold time
• On-time delivery to a clinical appointment
• SLA adherence with a hospital or pharmacy
• Temperature compliance
• Chain-of-custody documentation
• Cost-to-serve through returns, reattempts, and write-offs

Dynamic routing helps dispatchers respond before an exception becomes a deviation. It also gives teams a stronger operating model to manage delivery exceptions before they escalate into quality, service, or cost failures.

Static routing failures

Traditional systems often allocate time based on static averages. That is not precise enough for pharma cold chain.

A hospital receiving dock with security checks, lift access, and ward-level delivery may take materially longer than a pharmacy counter handoff. A clinic with a narrow receiving window may be more urgent than a geographically closer stop. A cryogenic or ultra-low-temperature shipment may need to be prioritised ahead of lower-risk deliveries even if that adds kilometres.

Static routing optimises the map. Cold chain orchestration optimises the outcome.

This is where automated route planning becomes critical: route decisions must be generated from live constraints, not fixed assumptions.

The “tribal knowledge” trap

Experienced drivers often know which hospital entrance to use, which pharmacy has limited receiving hours, which city streets are restricted at certain times, and where delivery handoffs regularly run long. When those drivers retire or leave, that operational knowledge disappears.

This matters because Europe’s driver workforce is ageing. Over 30% of European truck drivers are over the age of 55, with the average driver age at 44. Only 5–6% of the workforce is under 25. High HGV licensing costs—often exceeding €3,000 and representing three to four times the monthly minimum wage in many member states—make entry harder for younger workers.

Locus helps digitise execution intelligence so route quality does not depend entirely on individual driver memory.

Yard and depot dwell time

Cold chain risk can begin before the vehicle leaves the depot. Waiting for load readiness, dock availability, paperwork, or manual dispatch decisions consumes route time and packaging hold time.

When dock scheduling, route planning, dispatch, and execution data are disconnected, drivers lose time before the first delivery. A dispatch management platform for last-mile operations can help bring scheduling intelligence and execution control into the routing workflow.

Expert Supply Chain Consulting

Work with Locus to identify route, dispatch, and SLA bottlenecks in your healthcare logistics network—before they become cold chain deviations.

Learn More

Last-Mile Risk Mitigation for Temperature-Sensitive Drugs in Europe

Last-mile risk	Why it matters in pharma cold chain	Mitigation approach
Late depot departure	Reduces available packaging hold time before the first stop	Connect dock readiness, route release, dispatch automation, and ETA recalculation
Poor stop sequencing	Places sensitive or urgent shipments behind lower-risk deliveries	Prioritise stops by product sensitivity, receiving window, and clinical urgency
Urban congestion	Creates unpredictable route duration and temperature exposure	Use dynamic resequencing and real-time ETA monitoring
Door-open frequency	Increases exposure risk on multi-stop routes	Group compatible deliveries, reduce unnecessary handling, and sequence high-risk stops earlier
Failed first delivery	Creates return flows, reattempts, and excursion investigation risk	Use appointment-aware routing, recipient validation, and proactive customer communication
Driver knowledge gaps	New drivers may not know site-specific access or handoff requirements	Digitise stop instructions, service-time patterns, and delivery workflows
Manual exception handling	Slows response when temperature, traffic, or receiving issues arise	Use system-guided escalation, route reallocation, and documented exception workflows
Incomplete documentation	Weakens audit readiness and deviation investigation	Capture proof of delivery, timestamps, route logs, and exception records digitally

Real-World Impact: How a 3PL Used Locus’s AI to Scale Driver Yield

Cold chain networks need both compliance and capacity. The following example is not presented as a pharma-specific excursion reduction claim. It shows how a multi-country 3PL used Locus to improve driver productivity, route balance, and dispatch execution—capabilities directly relevant to healthcare logistics operations under capacity pressure.

Consider a mid-sized Third-Party Logistics provider operating a fleet of 450 vehicles across France, Germany, and the Benelux region.

The Challenge

The company faced a critical capacity problem. Driver turnover had reached 28% annually. Exit interviews showed that drivers felt overworked by unrealistic daily schedules and frustrated by constant mid-day route changes communicated by phone.

New drivers also needed up to three weeks of ride-alongs before they could independently manage complex urban routes without missing delivery windows.

For a pharma or healthcare logistics operator, the same symptoms create additional risk: missed SLAs, late hospital deliveries, inconsistent handoffs, and limited ability to recover from urgent exceptions.

The Locus AI Implementation

The 3PL replaced its legacy static dispatch system with Locus’s AI-powered, closed-loop Transportation Management System. The implementation focused on three pillars:

1. Digitising route and stop-level knowledge
2. Automating mid-day recalibration when plans changed
3. Improving predictive SLA modelling across complex urban delivery zones

Locus’s platform—deployed across 30+ countries—provided the routing intelligence and dispatch automation required for multi-market operations.

Learn more about Locus’s route optimisation platform

The Results

Within six months of deploying Locus’s AI routing engine, the network saw measurable improvements:

• 14% increase in stops per driver: AI-generated clusters based on geography, historical traffic, and service-time patterns helped drivers complete more stops per day without extending shift hours.
• Onboarding time reduced by 65%: Digital route guidance reduced reliance on senior-driver shadowing, cutting independent onboarding time from 21 days to 7 days.
• Empty miles reduced by 18%: Predictive capacity algorithms identified backhaul opportunities and co-ordinated pickups and drop-offs more effectively.
• Driver turnover dropped to 14%: More realistic, balanced routes reduced the stress created by impossible schedules and reactive phone-based dispatching.

For healthcare logistics teams, the same operating principles support better on-time delivery, lower cost-to-serve, improved route predictability, and stronger SLA performance.

---

How Locus’s AI Routing Acts as a Cold Chain Control Layer

Pharma cold chain execution requires more than planning a shortest path. It requires a control layer that can make route decisions based on service commitments, product sensitivity, driver capacity, vehicle capability, and real-time exceptions.

Locus does not manufacture cold chain packaging or temperature sensors. Instead, Locus orchestrates the delivery decisions around those systems. The platform helps dispatch teams turn order, route, vehicle, driver, telematics, and sensor data into executable plans and timely interventions.

1. Dynamic, mid-day resequencing

A static route can become obsolete minutes after departure. Traffic, failed deliveries, late depot loading, urgent orders, receiving delays, or sensor alerts can all require intervention.

Locus enables dispatchers to dynamically resequence routes while considering:

• Remaining delivery windows
• Driver hours
• Vehicle capacity
• Stop priority
• SLA commitments
• Route duration
• Customer or site availability
• Operational feasibility

For pharma cold chain, this matters because exception response time is often the difference between an on-time compliant delivery and a costly deviation.

2. Prioritising temperature-sensitive stops

Not every stop carries the same risk. A route may include standard refrigerated medicines, urgent biologics, clinical trial material, and controlled ambient products. The right sequence is not always the shortest geographic sequence.

Locus can help operators configure routing rules that prioritise:

• Time-critical hospital or clinic deliveries
• Products with shorter validated hold time
• Stops with strict receiving windows
• Patient-specific or procedure-specific shipments
• High-value loads requiring additional care
• Routes where failed delivery would create high cost-to-serve

This helps protect on-time delivery and SLA adherence where the operational consequences are highest.

3. Intelligent co-mingling of freight

Europe has a wider empty-mile problem. Nearly 23% of truck journeys run empty. In cold chain, the issue is not only empty kilometres but also poorly matched capacity: vehicles, compartments, drivers, and routes are not always used in the most efficient way.

Locus supports more intelligent planning across pickups, deliveries, returns, and backhauls. For healthcare networks, this can help reduce unnecessary miles while respecting product segregation, vehicle qualification, and service constraints.

Choosing the right route planning software is critical when the routing problem includes both cost and compliance.

4. Equitable, realistic scheduling

Overloaded routes lead to missed windows, rushed handoffs, driver stress, and higher exception volumes. Underloaded routes increase cost-to-serve.

Locus replaces blunt static assumptions with predictive ETAs and service-time models that reflect operational reality: location density, stop complexity, building type, historical dwell time, traffic, and time-window performance.

For pharma, realistic scheduling supports:

• Higher OTIF performance
• Reduced failed delivery risk
• Better driver compliance with SOPs
• Lower reattempt and return costs
• More credible route qualification evidence
• Stronger quality-team confidence in transport execution

For additional operational context, see how logistics teams can reduce failed deliveries with better transport workflows.

---

Benefits of AI-Powered Route Optimisation for Pharma Cold Chain Last Mile

AI-powered route optimisation delivers value across operations, finance, quality, and sustainability. In pharma cold chain, these benefits are connected: a more predictable route is often a safer, cheaper, and more compliant route.

Operational Benefits

• Higher on-time delivery performance: Routes are built around time windows, priority stops, service durations, and live conditions rather than static assumptions.
• Improved SLA adherence: Dispatch teams can monitor risk in execution and intervene before a delivery breach occurs.
• Reduced dwell and idle time: Better sequencing and dispatch automation cut avoidable waiting at depots, hospitals, pharmacies, and clinics.
• Faster exception response: Dynamic resequencing helps recover from traffic, failed delivery, order changes, or urgent clinical requirements.
• Stronger driver guidance: Digital workflows reduce dependence on tribal knowledge and help new drivers execute complex routes consistently.

Financial Benefits

• Lower cost-to-serve: Better route density, fewer failed deliveries, reduced overtime, and fewer unnecessary kilometres help control distribution cost.
• Reduced reattempts and returns: Appointment-aware routing and delivery feasibility checks reduce avoidable failed delivery workflows.
• Better fleet utilisation: Route optimisation helps match the right vehicle, driver, compartment, and route to the right workload.
• Lower exposure to write-offs and claims: While packaging and monitoring remain essential, smarter routing reduces avoidable conditions that contribute to excursions.

Driver salaries have risen 30–135% amid inflationary pressures, according to EURES-linked analysis. In that environment, every wasted driver hour has a higher cost impact.

Quality and Compliance Benefits

• Route-level auditability: Digital route logs, timestamps, proof of delivery, and exception records support investigation and audit readiness.
• Better deviation management: Dispatchers can link operational events—delay, reroute, failed delivery, alert—to corrective action workflows.
• GDP-aligned execution discipline: Routing rules can help enforce site, vehicle, driver, and service constraints defined by quality teams.
• Improved chain-of-custody visibility: Driver app workflows can support controlled handoff, recipient validation, and documented delivery completion.

Sustainability Benefits

• Fewer unnecessary miles: Route optimisation reduces wasteful travel and supports lower emissions.
• Reduced empty running: Predictive backhaul and co-ordinated pickup planning address the empty-journey problem.
• More efficient packaging strategy: When route duration and stop sequence are more predictable, operators can make better decisions about active and passive packaging requirements without overcompensating blindly.
• Lower waste: Fewer failed deliveries and fewer temperature-related exceptions mean less product and packaging waste.

Explore more route optimisation benefits

Strategic route planning is now a compliance lever

For pharma cold chain, route design should not be treated as a daily dispatch exercise alone. It is part of the quality operating model. Network leaders need to understand which depots, lanes, vehicles, service areas, delivery windows, and exception paths produce the lowest operational risk.

That makes strategic route planning essential for:

• Validating route feasibility before launches
• Modelling delivery risk by geography and product type
• Designing backup routes and contingency capacity
• Balancing cost-to-serve with SLA requirements
• Giving quality teams data-backed evidence for transport decisions

---

Why Choose Locus for Pharma Cold Chain Last Mile in Europe

Unlike generic route planners or legacy dispatch tools, Locus is built for enterprise logistics complexity. For pharma, healthcare distribution, and specialist 3PL networks, that complexity includes time windows, vehicle types, driver skills, product priorities, SLA rules, returns, pickups, compliance evidence, and dynamic exception handling.

Here is what differentiates Locus:

• Global scale, local precision: Locus has optimised 1.5B+ deliveries for 360+ enterprises across 30+ countries, including Europe, North America, India, Southeast Asia, and the Middle East.
• Closed-loop AI architecture: Locus does not only plan routes. It learns from execution data—actual arrival times, service durations, failed deliveries, driver performance, and SLA outcomes—to improve planning accuracy over time.
• Enterprise-grade flexibility: Locus adapts to complex operating rules, including vehicle types, driver skills, time windows, service areas, route duration, capacity, and regulatory constraints.
• Dispatch automation: Locus helps dispatch teams move away from manual phone-based exception handling to real-time, system-guided intervention.
• Cold chain orchestration fit: Locus can work alongside telematics, temperature monitoring, WMS, TMS, OMS, packaging, and quality systems to connect route decisions with execution data.
• Driver-centric design: Realistic workloads, clear mobile guidance, and fewer last-minute manual changes help protect driver experience and route performance.
• Analyst-recognised: Locus is recognised by leading analysts for innovation in logistics orchestration, giving enterprise buyers confidence in platform maturity.

“Locus helped us reduce empty miles by 18% across three countries in just six months.” — Leading European 3PL operator

For pharma manufacturers, wholesalers, healthcare distributors, and 3PLs, the operational question is no longer whether routing matters. It is whether your routing engine understands the constraints that determine product integrity, SLA performance, and cost-to-serve.

Why Route Optimisation Matters

Understand how AI-powered route optimisation improves logistics efficiency, reduces avoidable miles, protects driver productivity, and strengthens last-mile performance.

Explore Now

Conclusion: In Pharma Cold Chain, Routing Is a Quality Control

Europe’s pharma cold chain challenge is not only a storage, packaging, or monitoring problem. It is an execution problem.

The last mile concentrates the highest number of uncontrolled variables: traffic, access restrictions, dwell time, failed delivery, manual handoffs, driver availability, receiving windows, and real-time exceptions. For temperature-sensitive medicines, those variables directly affect on-time delivery, SLA adherence, cost-to-serve, and quality risk.

At the same time, the broader European logistics market is dealing with a structural driver shortage. The 426,000-driver deficit recorded in 2024 is projected to reach 745,000 by 2028. With 62% of trucking companies reporting severe or very severe recruitment challenges, pharma logistics teams cannot depend on extra capacity to absorb poor planning.

The practical response is orchestration. Locus helps enterprises build route plans that reflect real constraints, automate dispatch decisions, resequence dynamically, guide drivers, capture execution data, and support continuous improvement.

In pharma cold chain last mile Europe operations, smarter routing is not a marginal efficiency lever. It is a core mechanism for protecting product integrity, service reliability, and margin.

Schedule A Demo to see how Locus helps healthcare logistics teams improve cold chain last-mile execution across Europe.